GN-RESOUND
15.10.2015 07:32:58 CEST | Business Wire | Press release
GN ReSound, the leader in Smart Hearing™ aids, and Cochlear Limited (ASX:COH), the global leader in implantable hearing solutions, today announced a strategic alliance to develop the world’s smartest bimodal hearing solutions. This innovative collaboration will improve the hearing outcomes for more people of all ages with moderate to profound hearing loss. It will simplify the management of hearing solutions for hearing health professionals.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151014006759/en/
Cochlear and GN ReSound have had a successful history of collaborating on technology and product development, which started in 2011. The collaboration has brought to market the implantable hearing industry’s first bimodal solution using True Wireless™. With GN ReSound’s leading 2.4 GHz wireless technology, recipients of Nucleus® 6 and Baha® 5 implants can stream sound directly to their ears without wires or bulky neck-worn components.
To develop and commercialise the world’s smartest bimodal solutions, the Smart Hearing Alliance will significantly expand the existing collaboration. It will extend the market reach and offerings of both organisations, and leverage our technology leading positions in implantable hearing, hearing aids and wireless solutions.
The Smart Hearing Alliance will deliver bimodal solutions connecting Baha® bone conduction implants, Nucleus® cochlear implants, wireless accessories, Beltone and GN ReSound Smart Hearing™ aids, the first Made for iPhone hearing aids. Smart bimodal solutions will improve hearing outcomes and experiences, and simplify recipient management for hearing health professionals.
“This greatly expanded partnership makes incredible strides in bringing natural, effortless hearing to more consumers with the most severe types of hearing loss. We are thrilled to have the opportunity not only to strengthen our joint development, but also commercialise the smartest bimodal hearing solutions”, said GN ReSound CEO Anders Hedegaard and Cochlear CEO Chris Smith.
Mr Hedegaard said: “GN ReSound is committed to advancing what is possible for people with hearing loss. This collaborative offering will help us change the lives of so many more people.”
Mr Smith said: “This is a big step forward for our customers and professionals. The majority of cochlear implant recipients are bimodal users, so simplifying the management and improving the performance of their hearing solutions will be a huge benefit.”
The GN ReSound hearing aids used in these bimodal fittings will include the ReSound and Beltone brands. The Smart Hearing Alliance will be implemented by countries from early 2016.
About GN ReSound
GN ReSound is a leading international developer and manufacturer of advanced and innovative hearing healthcare solutions. The company offers a full range of hearing aids, accessories and diagnostic instruments under the ReSound, Beltone, Interton, and Otometrics brand names. GN ReSound’s revolutionary wireless technology allows wearers to personalize their hearing like never before. With its unique sound processing designed to mimic the natural ear, GN ReSound is making life sound better. ReSound’s revolutionary hearing aid technology is available through a global network of hearing care professionals. Consumers can find more information about ReSound’s portfolio of Smart Hearing aids on www.resound.com .
About Cochlear Limited
As the global leader in implantable hearing solutions, Cochlear is dedicated to bringing the gift of sound to people with moderate to profound hearing loss. Products include hearing solutions for cochlear, bone conduction and acoustic implants. We have helped over 400,000 people of all ages live full and active lives by reconnecting them with family, friends and community. We give our recipients the best lifelong hearing experience and access to innovative future technologies. For our professional partners, we offer the industry's largest clinical, research and support networks. That’s why more people choose Cochlear than any other hearing implant company.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151014006759/en/
Contact:
MEDIA:
GN ReSound
Jessica Larkin, 202-997-5582
jlarkin@mcbeestrategic.com
or
Cochlear
Ltd
Piers Shervington, +612 9425 5416
pshervington@cochlear.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom